Sunday, April 20, 2014 Last update: 12:33 PM
Fast Breaking Live News = 100's of Daily Sales Leads

Mylan Inc.

News articles for Mylan Inc.:

Friday, April 18, 2014

Wednesday, April 16, 2014

  • Mylan Launches First Generic ORTHO EVRA® Patch
    PITTSBURGH, April 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE(TM) (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA®* (Norelgestromin / Ethinyl Estradiol Transdermal System ... read more

Tuesday, April 15, 2014

  • Mylan Announces Settlement Agreement for First-to-File Generess® Fe
    PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Company, LLC, settling the parties' litigation in connection with Mylan's filing of an Abbreviated New Drug ... read more
  • Mylan Launches Generic Lunesta® Tablets
    PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its ... read more

Friday, April 11, 2014

Tuesday, April 8, 2014

Thursday, April 3, 2014

Monday, March 31, 2014

Thursday, March 27, 2014

  • Mylan Wins Breach of Contract Case against GlaxoSmithKline
    PITTSBURGH, March 27, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GlaxoSmithKline (GSK) ... read more

Monday, March 24, 2014

Thursday, March 13, 2014

Tuesday, March 11, 2014

  • Mylan Launches Naloxone Hydrochloride Injection
    PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection ... read more
  • Mylan Introduces Critical Care Segment in India
    MUMBAI, India and PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a Critical Care segment in India. The new segment focuses on anti-fungal, ... read more
  • Mylan Nominates JoEllen Lyons Dillon for Election to Board of Directors
    PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Board of Directors has nominated JoEllen Lyons Dillon as a candidate for election to Mylan's Board at the 2014 Annual Meeting of Shareholders to be held on April 11, 2014. If elected, ... read more

Saturday, March 1, 2014

Friday, February 28, 2014

  • Mylan to Present at the Barclays Global Healthcare Conference
    PITTSBURGH, Feb. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the Barclays Global Healthcare Conference on Tuesday, March 11, 2014, in Miami. The presentation is scheduled to begin ... read more
  • Mylan to Present at the Cowen and Company 34th Annual Health Care Conference
    PITTSBURGH, Feb. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the Cowen and Company 34(th) Annual Health Care Conference on Tuesday, March 4, 2014, in Boston. The presentation is ... read more

Thursday, February 27, 2014

Friday, February 14, 2014

Tuesday, February 11, 2014